Erasca (ERAS) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of -$0.10, in line with the company's recent trend of narrow losses as a clinical-stage biotech.
• No revenue is anticipated, consistent with Erasca's pre-commercial status focused on RAS/MAPK pathway therapies.
• Cash position remains robust at over $340 million post-Q4, bolstered by a $259 million financing in January 2026, extending runway into H2 2028.
• Investors will scrutinize pipeline updates, including progress on lead candidates and recent pancreatic cancer data that pressured shares.
• Historical EPS beats, like Q4 2025's -$0.10 vs. -$0.11 expected, could support positive sentiment if replicated.
• Strong Q1 2026 stock performance year-to-date underscores optimism around clinical advancements.

Earnings Context and Why It Matters

Erasca, Inc., a clinical-stage precision oncology company targeting the RAS/MAPK pathway, reports Q1 2026 earnings (three months ended March 31, 2026) amid heightened investor focus on biotech innovation. With no approved products, earnings spotlight operational efficiency, R&D (research and development) progress, and cash management. Recent milestones, including a major financing and pipeline option exercises, have fueled shares' strong Q1 performance, but a recent data readout dip highlights volatility. This report matters as it gauges sustainability of momentum in a competitive oncology landscape, informing views on trial timelines and funding needs.

Earnings Expectations

Consensus estimates peg Q1 2026 EPS at -$0.10, reflecting ongoing investment in clinical programs without revenue generation. This aligns closely with Q4 2025's reported -$0.10 per share, which beat expectations of -$0.11. Analysts anticipate stable R&D expenses around $25-30 million quarterly, down from prior peaks due to efficiency gains, with net losses moderated by the expanded cash pile.

Key metrics to watch include updates on lead assets like ERAS-601 and others in Phase 2 trials, enrollment progress, and any new data previews. Erasca has consistently narrowed losses and beaten EPS forecasts slightly in recent quarters, often leading to modest stock pops of 5-10%. Guidance may reaffirm cash runway into late 2028, providing visibility amid pipeline risks.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment is cautiously optimistic, buoyed by Erasca's Q1 2026 outperformance and analyst buy ratings (average target $18.27). Shares dropped 9% on April 13 after pancreatic cancer data underperformed expectations, but rebounded somewhat, trading around $17. Key risks include trial delays or further data misses in oncology, where binary outcomes drive volatility. Historical post-earnings moves average +/-10%, with beats supporting gains.

Forward Outlook and Key Factors to Monitor

Post-Q1 earnings, attention will shift to pipeline catalysts. Erasca's focus on RAS/MAPK inhibitors positions it in high-unmet-need areas like pancreatic and other cancers. Investors should monitor topline data readouts expected mid-2026, such as from ongoing Phase 2 trials, which could validate platform efficacy.

Cash burn trends are critical; with $340 million+ on hand plus recent raises, the company has flexibility through 2028, but R&D escalation for late-stage trials could pressure margins. Efficiency in G&A (general and administrative) and operating expenses will signal disciplined spending.

Broader dynamics include competitive landscape—M&A (mergers and acquisitions) activity in oncology—and regulatory milestones like FDA interactions. Positive guidance on enrollment or partnerships could lift shares, while delays might weigh on sentiment. Track SEC filings and conference calls for nuanced updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations